Transaction · 0000950170-25-014824

Schilke Tobin

Schilke Tobin, CFO, reported a transaction classified as grant at Revance Therapeutics, Inc. involving 6888.000000 shares for an estimated $0.00. Reported holdings after the transaction were 201554.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

grantSEC transaction code ACFO
RVNCRevance Therapeutics, Inc.
Filing timeFeb 06
Trade dateFeb 03, 2025
Filing · SECView on SEC
InsiderProfile

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
—
Pre-filing
1mo ago1w ago1d ago
Returns since
7d30d90d180d1y

RVNC price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
RVNC since 2025-02-06Filed 574 days ago · 30 days of pre-filing context shaded
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
grant
Code A
Identifier
0000950170-25-014824
Common Stock
Transaction date
Feb 03, 2025
Filed Feb 06, 2025, 12:53 AM · 3d delay
Shares
6.88k sh
$0 per share
Estimated value
$0
Computed from shares × price
Holdings after
201k sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $10.0MLarge $100M
Direct Ownership
-16score
Filing-only score

-16

Compact filing score computed from stored Form 4 facts. Version v1.

Mixed or weak signal

This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

CFO

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    Represents the vesting of performance-based restricted stock units (PSUs) granted on January 31, 2023, which vest over a three-year period based on the achievement of revenue goals. On February 3, 202…

Original filing · 0000950170-25-014824
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

RVNC